Mechanistic insights from sequential combination therapy with an SGLT2 inhibitor and DPP‐IV inhibitor: Results from the CANARIS trial using canagliflozin and teneligliptin
Okahata S et al. Diabetes Obes Metab 2018. doi: 10.1111/dom.13505
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.